Hackensack Meridian Health Research Institute Creates First Spin-off Company, EValuate Diagnostics
Hackensack Meridian Health Research Institute Creates First Spin-off Company, EValuate Diagnostics
The company, based on science from the Hackensack Meridian Center for Discovery and Innovation, promises to capture biomarkers for early diagnostics detecting cancer and a variety of diseases
該公司基於哈肯薩克子午線發現和創新中心的科學，承諾捕獲生物標記物，用於癌症和各種疾病的早期診斷
EDISON, N.J., Oct. 4, 2023 /PRNewswire/ -- The Hackensack Meridian Health Research Institute and its Office of Innovation and Commercialization have taken the step of establishing the first spin-off company based on science developed within the Hackensack Meridian Health network. The company aims to make tests detecting cancer and other diseases earlier than ever before.
新澤西州愛迪生，2023年10月4日/美通社/--哈肯薩克子午線健康狀況研究院及其創新和商業化辦公室採取步驟，建立了第一家以哈肯薩克子午線內發展的科學為基礎的剝離公司健康狀況網路。該公司的目標是比以往任何時候都更早地進行檢測癌症和其他疾病。
EValuate Diagnostics will market a new system for the capture of extracellular vesicles (EVs), including exosomes, which have been elusive to medicine thus far. Novel diagnostic assays derived from this technology will help select and identify disease biomarkers for earlier-than-ever detection of tumors and a wide range of other diseases.
評估診斷公司將推出一種新的系統來捕獲細胞外小泡(EV)，包括外體，到目前為止，藥物一直難以捉摸這些EV。從這項技術衍生出來的新的診斷分析將有助於選擇和識別疾病生物標記物，以便比以往更早地檢測腫瘤和廣泛的其他疾病。
"This is a remarkable breakthrough for our health network, and for patients of the future," said Robert C. Garrett, FACHE, chief executive officer of Hackensack Meridian Health. "We are taking the science produced by our terrific minds at the Hackensack Meridian Health Research Institute, and then moving it to the market so it can benefit all. Detecting deadly cancers as soon as possible means lives can, and will, be saved."
這對我們的健康網路和未來的患者來說都是一個了不起的突破。羅伯特·C·加勒特，哈肯薩克子午線公司首席執行官法希健康狀況。“我們正在研究哈肯薩克子午線由我們卓越的頭腦產生的科學。健康狀況研究機構，然後將其推向市場，使所有人都能受益。儘早發現致命的癌症意味著生命能夠並將被拯救。
The company is based upon the work of Olivier Loudig, Ph.D., an associate member of the Hackensack Meridian Center for Discovery and Innovation (CDI), who is directly involved with the development of EValuate Diagnostics. His Laboratory at the CDI has developed research programs for biomarker discovery and early detection of breast, lung, and prostate cancers using liquid biopsies.
該公司基於Hackensack子午線發現和創新中心(CDI)的準成員Olivier LouDig博士的工作，他直接參與了評估診斷的開發。他在CDI的實驗室開發了生物標記物發現和使用液體活檢早期檢測乳腺癌、肺癌和前列腺癌的研究計劃。
Developing cancer lesions, which may remain elusive due to their small size by traditional imaging approaches or tissue biopsies, still leave a molecular trace in biofluids such as blood. The laboratory of Dr. Loudig has homed in on this minute trail and, using highly sensitive next-generation-sequencing technologies, has been able to detect RNA signature indicative of the developing lesions. The development of gene expression assays for diagnostics is widely used for evaluating large tumors, but with this novel tracking technology, and applied to early detection has the potential to exponentially help save patient lives.
正在發生的癌症損傷，由於其體積小，在傳統的成像方法或組織活檢中可能仍然難以捉摸，但在血液等生物體液中仍會留下分子痕跡。勞迪格博士的實驗室一直專注於這一微小的追蹤，並利用高度敏感的下一代測序技術，已經能夠檢測到表明病變正在發展的RNA簽名。用於診斷的基因表達分析的發展被廣泛用於評估大型腫瘤，但利用這一新的跟蹤技術，並將其應用於早期檢測，有可能成倍地幫助挽救患者的生命。
"We are really establishing the threshold of detection," said Dr. Loudig recently.
“我們真的是在建立檢測的門檻，”勞迪格博士最近說。
A core tenet of the mission of the CDI, founded in 2019, is translating cutting-edge science to rapidly impact patient health for New Jersey's largest and most comprehensive health network. EValuate Diagnostics is a direct product of this research ethos, driving the discoveries of the Loudig Laboratory to help patients in the very near future.
CDI成立於2019年，其使命的核心宗旨是將尖端科學轉化為快速影響患者健康的新澤西州的最大、最全面的衛生網絡。評估診斷是這種研究精神的直接產物，推動了Loudig實驗室在不久的將來幫助患者的發現。
"This is a thrilling development," said Sandra Powell-Elliott, the chief innovation officer for Hackensack Meridian Health, who leads the network's Office of Innovation and Commercialization. "The health network supports so many great initiatives - but this is a new way for the health network to really bring innovation to the next level."
“這是一個激動人心的發展，”他說。桑德拉·鮑威爾-埃利奧特，哈肯薩克子午線公司的首席創新官健康狀況，他領導著該網路的創新和商業化辦公室。醫療網路支持了這麼多偉大的舉措--但這是醫療網路真正將創新推向下一個層次的新途徑。
"This is a new milestone for innovation at Hackensack Meridian Health," said Ihor Sawczuk, M.D., FACS, Hackensack Meridian Health's president of Academics, Research and Innovation, founding chair of the Hackensack Meridian Health Research Institute, and also associate dean of Clinical Integration and professor and chair emeritus of Urology at the Hackensack Meridian School of Medicine. "The work of Olivier Loudig is promising, and we want to fulfill that promise with all the support we can provide."
這是哈肯薩克子午線創新的新里程碑健康狀況，“說Ihor Sawczuk，醫學博士，FACS，Hackensack子午線健康的總裁，學術、研究和創新，哈肯薩克子午線創始主席健康狀況他也是哈肯薩克子午線醫學院臨床整合副院長、泌尿外科教授和名譽主席。奧利維爾·勞迪格的工作前景看好，我們希望盡我們所能實現這一承諾。
The Office of Innovation and Commercialization launched in 2022 and promises to support innovations and discoveries across Hackensack Meridian Health. One of its marquee programs so far is the Bear's Den - an innovation incubator launched in 2017 which brings together a panel of experts, including Hackensack Meridian Health CEO Garrett, leading physicians, key network executives, venture capitalists, patent attorneys, who gather regularly to vet proposals from entrepreneurs. The health network's novel incubator has vetted many products and strategies to streamline care delivery, reduce infections, lower hospital readmissions and help patients partner in their care with physicians. The program has also invested in promising innovative companies.
創新和商業化辦公室成立於2022年，承諾支持整個哈肯薩克子午線的創新和發現健康狀況。到目前為止，它的一個重要專案是Bear‘s Den，這是一個創新孵化器，於2017年推出，匯集了包括Hackensack Meridian在內的專家小組健康狀況首席執行官加勒特、頂尖醫生、關鍵網路高管、風險資本家、專利律師，他們定期聚集在一起審查企業家的提案。該健康網路的新型孵化器已經審查了許多產品和戰略，以簡化護理提供，減少感染，降低再次住院人數，並幫助患者與醫生合作護理。該計劃還投資了前景看好的創新公司。
ABOUT HACKENSACK MERIDIAN HEALTH
Hackensack Meridian Health is a leading not-for-profit health care organization that is the largest, most comprehensive and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care. The network has 18 hospitals and more than 500 patient care locations, which include ambulatory care centers, surgery centers, home health services, long-term care and assisted living communities, ambulance services, lifesaving air medical transportation, rehabilitation centers, urgent care centers, physician practice locations, and a fitness and wellness center. With more than 35,000 team members and 7,000 physicians, Hackensack Meridian Health is a distinguished leader in health care philanthropy and committed to the health and well-being of communities throughout New Jersey.
約哈肯薩克子午線健康狀況
哈肯薩克子午線健康狀況是一家領先的非營利性醫療保健組織，是全球最大、最全面和真正一體化的醫療保健網絡新澤西，提供全方位的醫療服務、創新研究和改善生活的護理。該網路擁有18家醫院和500多個患者護理地點，其中包括門診護理中心、手術中心、家庭健康服務、長期護理和輔助生活社區、救護車服務、救生空中醫療運輸、康復中心、緊急護理中心、醫生執業地點以及健身和健康中心。擁有超過35,000名團隊成員和7,000名醫生，哈肯薩克子午線健康狀況是醫療保健慈善事業的傑出領導者，致力於整個社區的健康和福祉新澤西。
The network's notable distinctions include having more U.S. News-ranked hospitals than any other health system in New Jersey, as ranked by U.S. News & World Report, 2022-23. Hackensack University Medical Center is nationally-ranked by U.S. News & World Report in four specialties, more than any other hospital in New Jersey. Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, and K. Hovnanian Children's Hospital at Jersey Shore University Medical Center, are ranked #1 in the state and top 20 in the Mid-Atlantic Region by U.S. News & World Report's 2023-24 Best Children's Hospital Report. Additionally, their combined nephrology, urology, cancer, and neurology/neurosurgery programs rank in the top 50 in the United States. To learn more, visit .
該網路的顯著區別包括擁有更多美國新聞-醫院排名超過其他任何醫療系統新澤西，按以下順序排列《美國新聞與世界報道》，2022-23年。哈肯薩克大學醫學中心在全國範圍內排名《美國新聞與世界報道》在四個專科，比其他任何一家醫院都要多新澤西。哈肯薩克大學醫學中心的約瑟夫·M·桑扎裡兒童醫院和澤西海岸大學醫學中心的K·霍夫納尼亞兒童醫院在該州排名第一，在大西洋中部地區排名前20。《美國新聞與世界報道》2023-24年度最佳兒童醫院報告。此外，他們的腎病學、泌尿科、癌症和神經病學/神經外科課程在美國。要了解更多資訊，請訪問。
ABOUT THE CENTER FOR DISCOVERY AND INNOVATION
關於發現和創新中心
The Center for Discovery and Innovation, a member of Hackensack Meridian Health, translates current innovations in science to improve clinical outcomes for patients. More than 29 laboratories, 185 professional researchers and physician-scientists at the CDI have set their sights on cancer, infectious diseases, autoimmune disorders, and other acute and chronic diseases. Clinical need drives the scientific insights, and their application, for these researchers, as shown in the real-time response to the COVID-19 pandemic, resulting in new diagnostics, therapies, and surveillance abilities. The CDI leverages a new wave of scientific advances involving genetics, cell engineering of the human immune system, and imaging to better diagnose, treat and prevent disease through personalized medicine approaches. For additional information, please visit .
Hackensack子午線健康中心的成員之一，發現和創新中心，將當前的科學創新轉化為改善患者的臨床結果。CDI的29個實驗室、185名專業研究人員和內科科學家將目光投向了癌症、傳染病、自身免疫性疾病和其他急慢性疾病。臨床需求推動了這些研究人員的科學見解及其應用，正如對新冠肺炎大流行的實時反應所顯示的那樣，從而產生了新的診斷、治療和監測能力。CDI利用涉及遺傳學、人類免疫系統細胞工程和成像的新一波科學進步，通過個性化醫學方法更好地診斷、治療和預防疾病。欲瞭解更多資訊，請訪問。
ABOUT HACKENSACK MERIDIAN HEALTH RESEARCH INSTITUTE (HMHRI):
HMHRI leads and organizes a connected ecosystem bringing together clinicians, scientists, and educators to respond to the health problems of our time, in real-time. HMHRI is dedicated to accelerating discovery, innovation, and translation of scientific breakthroughs that address unmet clinical needs.
約哈肯薩克子午線健康研究所(HMHRI)：
HMHRI領導和組織一個互聯的生態系統，將臨床醫生、科學家和教育工作者聚集在一起，即時應對我們這個時代的健康問題。HMHRI致力於加速發現、創新和轉化解決未滿足的臨床需求的科學突破。
SOURCE Hackensack Meridian Health
來源：Hackensack子午線健康